INAB IN8BIO, INC.
Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1740279 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY6.1%
TTM EPS YoY80.8%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-141.8%
ROA-109.4%
ROIC (approx.)-1,362.1%
Asset turnover—
Leverage & solvency
Liabilities / assets24.2%
Debt / equity0.00x
Current ratio5.78x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.76x
Accruals ratio-26.2%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | — | — | — | — | — |
| R&D expense | $10.21M | $16.96M | $16.83M | $14.06M | $7.35M |
| SG&A expense | $9.65M | $12.64M | $13.51M | $14.46M | $7.31M |
| Operating income | -$19.44M | -$30.44M | -$30.01M | -$28.52M | -$14.65M |
| Pretax income | -$19.44M | -$30.68M | — | — | — |
| Income tax | $0 | $0 | $0 | $0 | $0 |
| Net income | -$19.44M | -$30.44M | -$30.01M | -$28.52M | -$14.65M |
| EBITDA | -$18.44M | -$29.46M | -$29.05M | -$28.37M | -$14.56M |
| EPS (basic) | -4.44 | -17.05 | -1.00 | -1.36 | -1.47 |
| EPS (diluted) | -4.44 | -17.05 | -1.00 | -1.36 | -1.47 |
| Weighted avg. shares (diluted) | 4.37M | 1.78M | 29.86M | 20.97M | 9.97M |
| Balance sheet | |||||
| Cash & equivalents | $27.31M | $11.39M | $21.54M | $18.43M | $37.27M |
| Current assets | $27.88M | $12.58M | $24.62M | $22.23M | $38.98M |
| PP&E, net | $1.86M | $2.86M | $3.51M | $4.40M | $97,000 |
| Total assets | $32.28M | $20.94M | $33.71M | $33.04M | $42.22M |
| Current liabilities | $3.16M | $3.08M | $5.39M | $5.82M | $2.26M |
| Total liabilities | $4.72M | $6.47M | $8.77M | $10.31M | $4.04M |
| Shareholders' equity | $27.56M | $14.48M | $24.94M | $22.73M | -$38.18M |
| Shares outstanding | 9.77M | 2.42M | 43.29M | 24.55M | 18.78M |
| Cash flow statement | |||||
| Operating cash flow | -$12.71M | -$24.15M | -$23.34M | -$24.12M | -$13.51M |
| Investing cash flow | $0 | -$187,000 | -$600,000 | -$3.71M | -$309,000 |
| Financing cash flow | $28.64M | $14.18M | $27.04M | $8.99M | $32.95M |
| Depreciation & amortization | $1.00M | $976,000 | $962,000 | $147,000 | $89,000 |
| Stock-based compensation | $3.19M | $5.00M | $4.37M | $3.47M | $2.19M |
Free plan shows the latest 5 periods; Pro shows all 6 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.